Minerva Neurosciences, Inc. (NASDAQ:NERV – Get Free Report)’s share price crossed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $2.80 and traded as low as $2.58. Minerva Neurosciences shares last traded at $2.60, with a volume of 18,036 shares changing hands.
Wall Street Analyst Weigh In
NERV has been the topic of a number of analyst reports. StockNews.com started coverage on shares of Minerva Neurosciences in a research report on Wednesday. They issued a “sell” rating on the stock. HC Wainwright reduced their price objective on Minerva Neurosciences from $7.00 to $5.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 7th.
Check Out Our Latest Analysis on Minerva Neurosciences
Minerva Neurosciences Trading Down 1.9 %
Minerva Neurosciences (NASDAQ:NERV – Get Free Report) last issued its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.12). As a group, equities analysts anticipate that Minerva Neurosciences, Inc. will post -2.26 earnings per share for the current year.
Minerva Neurosciences Company Profile
Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.
Read More
- Five stocks we like better than Minerva Neurosciences
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- NVIDIA’s AI Dominance: Why Analysts Predict Major Upside Ahead
- Low PE Growth Stocks: Unlocking Investment Opportunities
- These Stocks Are Using Buybacks to Unlock Big Gains for Investors
- High Flyers: 3 Natural Gas Stocks for March 2022
- This Is the Entry Into PepsiCo You’ve Been Waiting For
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.